<DOC>
	<DOCNO>NCT02271464</DOCNO>
	<brief_summary>This study consist 4-months induction first-line chemotherapy G.O.N.O . FOLFOXIRI regimen plus bevacizumab follow maintenance bevacizumab bevacizumab plus metronomic chemotherapy ( capecitabine cyclophosphamide ) mCRC patient . The main objective study preliminarily evaluate potential effect combination metronomic chemotherapy capecitabine cyclophosphamide maintenance bevacizumab pharmacodynamic clinical parameter among mCRC patient .</brief_summary>
	<brief_title>Maintenance Bevacizumab Only Bevacizumab Plus Metronomic Chemotherapy Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Histologically proven diagnosis colorectal cancer . Not resectable metastatic colorectal cancer previously treat chemotherapy metastatic disease . At least one measurable lesion accord RECIST criterion . Male female 1875 year age . ECOG PS &lt; 2 age &lt; 71 year , ECOG PS = 0 aged 7175 year ; Life expectancy least 12 week . Previous adjuvant chemotherapy contain oxaliplatin allow 12 month elapse end adjuvant therapy first relapse ; Previous adjuvant chemotherapy fluoropyrimidine monotherapy allow 6 month elapse end adjuvant first relapse ; Neutrophils 1.5 x 109/L , Platelets 100 x 109/L , Hgb &gt; 9 g/dl . Total bilirubin 1.5 time uppernormal limit ( UNL ) institutional normal value ASAT ( SGOT ) and/or ALAT ( SGPT ) 2.5 x UNL , 5 x UNL case liver metastasis , alkaline phosphatase 2.5 x UNL , 5 x UNL case liver metastasis . Creatinine clearance &gt; 50 mL/min serum creatinine 1.5 x UNL . Urine dipstick proteinuria &lt; 2+ . Patients discover 2+ proteinuria dipstick urinalysis baseline , undergo 24hour urine collection must demonstrate &lt; 1 g protein/24 hr . Written informed consent treatment translational analysis . Radiotherapy site within 4 week study . Previous treatment bevacizumab Untreated brain metastasis spinal cord compression primary brain tumour . History evidence upon physical examination CNS disease unless adequately treat . Symptomatic peripheral neuropathy &gt; 2 grade NCICCTG criterion ; Serious , nonhealing wound , ulcer , bone fracture . Evidence bleed diathesis coagulopathy . Uncontrolled hypertension . Clinically significant ( i.e . active ) cardiovascular disease example cerebrovascular accident ( ≤6 month ) , myocardial infarction ( ≤6 month ) , unstable angina , New York Heart Association ( NYHA ) grade II great congestive heart failure , serious cardiac arrhythmia require medication . Current recent ( within 10 day prior study treatment start ) ongoing treatment anticoagulant therapeutic purpose . Chronic , daily treatment highdose aspirin ( &gt; 325 mg/day ) . Treatment investigational drug within 30 day prior enrollment . Other coexist malignancy malignancy diagnose within last 5 year exception basal squamous cell carcinoma cervical cancer situ . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study treatment start , anticipation need major surgical procedure course study . Lack physical integrity upper gastrointestinal tract , malabsorption syndrome , inability take oral medication . Pregnant lactating woman . Women childbearing potential either positive pregnancy test baseline . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Sexually active male female ( childbearing potential ) unwilling practice contraception study ( barrier contraceptive measure oral contraception ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>Ist line therapy</keyword>
	<keyword>metronimic therapy</keyword>
	<keyword>bevacizumab</keyword>
</DOC>